市場調查報告書
商品編碼
1519491
2024-2032 年按類型、技術、應用和地區分類的基因檢測市場報告Genetic Testing Market Report by Type, Technology, Application, and Region 2024-2032 |
IMARC Group年全球基因檢測市場規模達177億美元。這個市場主要由技術進步、大眾對個人化醫療的需求不斷成長、遺傳性疾病患病率增加、政府支持性舉措的訂定以及倫理、法律和社會考慮的影響不斷增加所推動。
市場成長與規模:隨著公眾的資訊更加豐富以及對個人化醫療的需求增加,該產業正在強勁成長。隨著檢測技術的進步,市場正在以極快的速度滲透到新的醫療保健領域,並已成為醫療保健行業中最具活力的領域之一。
主要市場促進因素:主要因素是新技術的引入、遺傳疾病和慢性病盛行率的增加以及消費者對遺傳風險知識的增加。政府對基因研究的舉措和資助也極大地幫助了該行業的市場成長,這為基因檢測市場有多大提供了準確的答案。
技術進步:NGS(下一代定序)和 CRISPR 技術的創新徹底改變了測試,提供了精確且經濟實惠的方法。這些發展擴大了基因檢測的範圍和機會,從而增加了其在臨床環境和研究中的使用。
產業應用:檢測應用包括癌症診斷、遺傳疾病診斷、心血管疾病診斷等。它可用於診斷和管理遺傳疾病,使其成為現代醫療保健不可分割的一部分。
主要市場趨勢:人們越來越喜歡直接面對消費者的服務,在這種服務中,使用者無需醫生干預即可獲取遺傳資訊。市場也經歷了一種趨勢,即檢測正在成為疾病篩檢和管理的常規醫療保健實踐的一部分,這表明基因檢測市場的未來前景樂觀。
地理趨勢:北美佔據市場主導地位,其次是歐洲和亞太地區。醫療設施、人均醫療支出和政府援助等因素也促進了這些地區的發展。儘管當前面臨挑戰,拉丁美洲、中東和非洲的新興市場仍顯示出成長潛力。
競爭格局:市場競爭激烈,主要參與者從事研發、策略夥伴關係和監管合規。這些公司專注於擴大其測試產品組合併探索新的市場機會以保持競爭優勢。
挑戰與機會:雖然市場提供了大量的成長機會,但它也面臨著諸如測試的道德和法律影響、對熟練專業人員的需求以及公眾認知問題等挑戰。應對這些挑戰並利用技術進步為市場擴張和創新提供了重大機會。
基因檢測技術的進步
基因檢測技術的進步有助於推動基因檢測市場的規模。這些技術創新帶來了更準確、更有效率、更具成本效益的基因分析方法,將檢測範圍擴大到腫瘤學、藥物基因組學和預測檢測等領域,進一步推動基因檢測市場的成長。增強型定序技術,例如下一代定序(NGS),可以提供對遺傳性疾病的詳細了解,從而實現早期檢測和個人化治療計劃。例如,
一項針對1914 名女性的研究表明,與標準篩檢相比,cfDNA 檢測顯著降低了21 三體和18 三體的假陽性率,檢測非整倍體的成功率為100%,預測值更高。此外,簡化的流程增加了基因檢測在各種醫療保健環境中的採用,從而促進了基因檢測市場的需求。
對個人化醫療的認知和需求不斷增加
對個人化醫療的認知和需求的不斷提高也在塑造基因檢測市場前景方面發揮了重要作用。個人化醫療依賴遺傳資訊來客製化治療,這增加了對基因測試的需求。這種需求在腫瘤學和生殖健康等領域尤其明顯,在這些領域,基因檢測指導治療決策並評估後代的遺傳性疾病風險。例如,根據一項研究,回覆率為 36% 的調查顯示,312 名受訪者中,83% 對直接面對消費者的基因檢測詢問最少,14% 涉及結果解釋,超過 50% 的人支持遺傳諮詢師和臨床環境進行基因檢測,70% 的人願意考慮對有隱私、匿名或訪問問題的患者進行基因檢測。此外,消費者對了解健康狀況遺傳傾向的興趣日益濃厚,進一步推動了基因檢測市場的概況,推動了基因檢測市場統計數據和基因檢測市場趨勢。
遺傳性疾病和慢性病的增加
全球遺傳性疾病和慢性病的增加進一步加劇了基因檢測市場的統計數據。基因檢測在囊性纖維化、鐮狀細胞性貧血和亨廷頓舞蹈症等各種疾病的早期檢測、診斷和治療中發揮著至關重要的作用。此外,隨著癌症、心血管疾病和糖尿病等慢性疾病發生率的不斷增加,越來越需要透過檢測來識別導致個體易患這些疾病的基因突變。世界衛生組織 (WHO) 報告稱,癌症、心血管疾病和糖尿病等非傳染性疾病 (NCD) 每年造成全球死亡人數的 73%。基因檢測可以幫助識別有這些疾病風險的個體。透過測試進行早期發現可以改善患者的治療結果,進一步推動基因檢測市場的發展。基因檢測市場規模龐大,美國等已開發國家每年基因檢測數量大幅增加。展望未來,基因檢測的未來充滿希望,技術的持續進步有望提高準確性和可及性。妊娠基因檢測也變得越來越普遍,為胎兒健康和遺傳狀況提供了寶貴的見解。
The global genetic testing market size reached US$ 17.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 43.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The market is primarily driven by technological advancements, rising demand for personalized medicine among the masses, increased prevalence of genetic disorders, introduction of supportive government initiatives, and rising implication of ethical, legal, and social considerations.
Market Growth and Size: The sector is seeing strong growth as the public becomes more informed and the appetite for personalized medicine increases. With advancements in testing technologies, the market is penetrating new healthcare sectors at an extremely rapid pace and has become one of the most dynamic segments of the healthcare industry.
Major Market Drivers: The main factors are the introduction of new technologies, the increase in the prevalence of genetic diseases and chronic conditions and the increasing of the consumer's knowledge about genetic risks. Government initiatives and funding of genetic research also greatly assist the industry in market growth, which provide an accurate answer to how big is the genetic testing market.
Technological Advancements: Innovations in NGS (next-generation sequencing) and CRISPR technologies have revolutionized testing providing precise and budget-friendly methods. These developments have enlarged the range and opportunity of genetic testing, which in turn has increased the usage of it both in clinical settings and in research.
Industry Applications: The application of the testing includes cancer diagnosis, genetic disease diagnosis, and cardiovascular disease diagnosis. It can be used for diagnosing and managing genetic diseases makes it an inseparable part of modern healthcare.
Key Market Trends: There is a rising preference for direct-to-consumer services, in which users can acquire genetic information without using an intervening doctor. The market is also experiencing a trend where testing is becoming part of regular healthcare practices for disease screening and management, which indicates a positive outlook for the future of genetic testing market.
Geographical Trends: North America dominates the market, followed by Europe and the Asia Pacific. Factors including healthcare facilities, per capita medical expenditure, and governmental assistance also contribute to the development of these regions. Emerging markets in Latin America and the Middle East and Africa show potential for growth despite current challenges.
Competitive Landscape: The market is highly competitive with key players engaging in research and development, strategic partnerships, and regulatory compliance. These companies are focusing on expanding their testing portfolios and exploring new market opportunities to maintain their competitive edge.
Challenges and Opportunities: While the market offers substantial growth opportunities, it faces challenges such as ethical and legal implications of testing, the need for skilled professionals, and public perception issues. Addressing these challenges and harnessing technological advancements present significant opportunities for market expansion and innovation.
Advancements in genetic testing technologies
Advancements in genetic testing technologies have been instrumental in driving the genetic testing market size. These technological innovations have led to more accurate, efficient, and cost-effective genetic analysis methods, expanding the scope of testing into areas such as oncology, pharmacogenomics, and predictive testing, further driving the genetic testing market growth. Enhanced sequencing techniques, such as next-generation sequencing (NGS), provide detailed insights into genetic disorders, enabling early detection and personalized treatment plans. For instance,
A study on 1914 women revealed cfDNA testing significantly reduces false positives for trisomies 21 and 18 compared to standard screening, with a 100% success rate in detecting aneuploidies and higher predictive values. Furthermore, simplified processes have increased the adoption of genetic testing across various healthcare settings, contributing to the genetic testing market demand.
Increasing awareness and demand for personalized medicine
Increasing awareness and demand for personalized medicine have also played a significant role in shaping the genetic testing market outlook. Personalized medicine, which relies on genetic information to tailor treatments, has heightened the demand for genetic tests. This demand is particularly evident in sectors such as oncology and reproductive health, where genetic testing guides therapy decisions and assesses genetic disorder risks in offspring. For example, according to a study, survey with a 36% response rate showed that 83% of the 312 respondents had minimal inquiries about direct-to-consumer genetic testing, 14% dealt with result interpretation, and over 50% supported the role of genetic counsellors and clinical settings for genetic testing, with 70% open to considering it for patients with privacy, anonymity, or access concerns. Additionally, growing consumer interest in understanding genetic predispositions to health conditions further fuels genetic testing market overview, driving genetic testing market statistics and genetic testing market trends.
Rise in genetic disorders and chronic diseases
The rise in genetic disorders and chronic diseases globally is further escalating the genetic testing market statistics. Genetic testing plays a vital role in the early detection, diagnosis, and management of various conditions such as cystic fibrosis, sickle cell anemia, and Huntington's disease. Moreover, with the increasing incidence of chronic diseases, including cancer, cardiovascular diseases, and diabetes, there is a heightened need for testing to identify genetic mutations predisposing individuals to these conditions. The World Health Organization (WHO) reports that non-communicable diseases (NCDs), such as cancer, cardiovascular diseases, and diabetes, are responsible for 73% of global deaths annually. Genetic testing can help identify individuals at risk for these conditions. Early detection through testing improves patient outcomes, further propels the genetic testing market. The genetic testing market is substantial, with a considerable growth in the number of genetic testing per year in USA and other developed countries. Looking ahead, the future of genetic testing is promising, with continued technological advancements expected to enhance accuracy and accessibility. Genetic testing in pregnancy is also becoming increasingly prevalent, providing valuable insights into fetal health and genetic conditions.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on type, technology, and application.
Predictive and Presymptomatic Testing
Carrier Testing
Prenatal and Newborn Testing
Diagnostic Testing
Pharmacogenomic Testing
Others
Diagnostic testing accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the type. This includes predictive and presymptomatic testing, carrier testing, prenatal and newborn testing, diagnostic testing, pharmacogenomic testing, and others. According to the report, diagnostic testing represented the largest segment.
The largest sector of the market is the diagnostic testing market, which is employed to reveal or confirm specific inherited disease in symptomatic people. This sector is on the rise due to its contribution to a precise diagnosis, which is necessary for appropriate treatment and control of a plethora of genetic conditions. The fact of its broad fields of using from rare genetical diseases till common conditions brings attention to this issue in medical sector. An investigation that appeared in the Journal of Molecular Diagnostics revealed that the percentage of medical professionals who had integrated genetic diagnostic testing for hereditary cancers definitely had grown from 19.8% in 2014 to 38.4% in 2018.
Cytogenetic Testing and Chromosome Analysis
Biochemical Testing
Molecular Testing
DNA Sequencing
Others
Molecular testing holds the largest share in the industry
A detailed breakup and analysis of the market based on the technology have also been provided in the report. This includes cytogenetic testing and chromosome analysis, biochemical testing, and molecular testing (DNA sequencing, and others). According to the report, molecular testing accounted for the largest market share.
Molecular testing represents the largest section in the market. The methodology portion cover PCR, NGS, and other filtered DNA related analysis terms. It is very practical as it can be applied for many sections, from detecting genetic changes that give rise to diseases, to exploring cancer genetics for the reason of targeted treatments, and to unearthing genetic predispositions for different conditions. The unique capability of molecular testing associated with the precision it offers has established the field of genetic diagnostics, individualized medicine, and research as a key area in molecular science, giving it a leading position in this field. A 2021 study evaluated various COVID-19 molecular tests, revealing a high sensitivity rate of 95.9% for minimizing false negatives, and a specificity rate of 97.2% to reduce false positives. Besides, cytogenetic testing, including chromosome analysis means looking through section of chromosome in attempted to get information about chromosomal abnormalities of the patient. This part has a vital role in recognition the chromosome count, missing only one chromosome could cause genetic disorders such as Down syndrome, Klinefelter syndrome or Turner syndrome. It is widely use in pre-natal testing, cancer diagnosis and also for studying cells chromosome change, which are hardly beyond disease.
The biochemical testing, on the other hand, is directed towards the measurement of the exact amount of activity in most cases of specific enzymes in the body or the levels of proteins, hormones and other substances that comprise the body. This segment is a vital step in identifying metabolic disorders that result from enzyme deficiency by determining conditions like PKU or Tay- Sachs Disease, as possible causes.
Cancer Diagnosis
Genetic Disease Diagnosis
Cardiovascular Disease Diagnosis
Others
Genetic disease diagnosis represents the leading market segment
The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer diagnosis, genetic disease diagnosis, cardiovascular disease diagnosis, and others. According to the report, genetic disease diagnosis represented the largest segment.
Genetic testing is currently utilized to diagnose a large number of diseases that are affected by both single-gene and multiple-gene factors. Genetic disease diagnosis is essential for the early detection of diseases and prompt intervention that finally aid in the condition's management. This growth is powered by its rear-rooted importance in the field of medicine which is represented in the accurate diagnoses of the genetic diseases not only for treatment but also for family planning. Between 2012 and 2022, the US led in the expansion of genetic tests, primarily for clinical diagnosis, highlighting the need for mandatory reporting and international collaboration for a comprehensive understanding of global genetic testing.
Using genetic analysis for cancer diagnosis implies finding out genetic mutations or alterations which cause cancer to develop. This portion is very vital for early tumor detection, diagnosis and controlling different categories of cancer.
Moreover, the genetic diagnosis of cardiovascular diseases involves locating these genetic variants to establish an increased risk for such heart-related defects as congenital heart defects, various cardiomyopathies, and arrhythmias.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest genetic testing market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America is the largest segment in the world market, driven by the world class healthcare infrastructure, the high amount of money that is spent on the healthcare sector and the presence of top companies and research institutions. The region is propelled by strong private investment, in the field of personalized medicine, large investments by governments in gene research, and favorable policy decisions from the national government. Besides, genetic disorders as well as chronic diseases, with a growing number of patients and informed population ready to access testing services, boost propel this company's leading position in the market.
The European region remains of crucial importance in terms of the market structure which is based on well-developed healthcare systems and governmental financial support of genetic research. The locale's market growth is propelled by the growing awareness about genetic DNA, personalized medicine, and the availability of qualified personnel in the field of genetics.
The Asia Pacific region is experiencing a growing market come from the fact that it is a large population base, infrastructure on healthcare rising and increasing the expenditure on healthcare. The market also draws support from genetic disease awareness growth, personalized medicine demanded growth, and government initiatives in health care reform.
The Latin American market is developing steadily, it is stimulated by improvement of the healthcare infrastructure, by the growth of the wages, and by the increase in public health awareness. As region is faced with the increasing demand for testing services for diseases prevention, diagnosis, and treatment.
The middle east and Africa market holds a lot of promise of significant growth. Factors that include the rising number of healthcare expenditure, the growing prevalence of genetic diseases, as well as the heightened level of awareness of the significant effects of genetic testing across the industry are the major drivers of genetic testing in this part of the world.
Market's key players adopt different strategies to achieve fundamental objective of strengthening their market share. This include is investing heavily in research and development to innovation and evolution of genetic testing technologies, especially in the direction of next-generation sequencing (NGS) and CRISPR. They also engage in the establishment of partnerships and collaboration with other biotech companies, academic institutions, as well as healthcare providers to help them grow in their services portfolio and geographical reach. Besides this, manufacturers are making efforts to get the new devices approved by the regulator agencies to be in compliance with regulations and guarantee the patient safety. Additionally, direct-to-consumer services have been developed with the aim of leveraging consumers' growing demand for personalized healthcare and genetic wellness.
23andme Inc.
Ambry Genetics Corporation (Konica Minolta Healthcare Americas Inc.)
Bio-RAD Laboratories Inc.
Cepheid (Danaher Corporation)
Eurofins Scientific
Illumina Inc.
Invitae Corporation
Luminex Corporation (DiaSorin)
Myriad Genetics Inc.
QIAGEN
Quest Diagnostics
Thermo Fisher Scientific
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)